Clinical Trial Update: Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating hypofractionated radiotherapy with a PD-1 inhibitor followed by GM-CSF and IL-2 for advanced refractory solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• IL-2 (Interleukin-2)
• PD-1 inhibitor

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Advanced Refractory Solid Tumors | Phase 2 | Status: UNKNOWN